The features of control of arterial hypertension in Mongolia (literature review)

The complications of arterial hypertension cause more than a half of 17 million cases of cardiovascular mortality in the world. According to the official statistics in 2010 Mongolia was the leader among the countries of the Asian Pacific region in mortalityfrom complications connected with arterial hypertension (40.9 people per 100 000 of population). It is proved that lifestyle change with risk factors correction and adequate hypotensive therapy allow to control arterial hypertension in most patients. The real prevalence of the resistant arterial hypertension in the world is less than 10 %. However, in clinical practice even in countries with high income only 50-60 % of persons with arterial hypertension can reach the target blood pressure values less than 140/90 mmHg, in Mongolia, these indicators are worse. Such situation leads to growth of mortality and disability, therefore it is a serious worldwide problem for health care. There are four reasons, which lead to low compliance of patients to be treated: social and administrative problems; medical passivity; irrational therapy and low adherence of patients to recommendations of doctors. But according to different cohort studies, the main reason of poor control of arterial hypertension in Mongolia is insufficient hypotensive therapy, therefore only 23.6 % patients can achieve the target blood pressure values. In such conditions, it is too important to develop a strategy aimed at improving control of arterial hypertension in Mongolia.

Mongolia, risk factors, control of arterial hypertension, target blood pressure values, adherence, hypotensive therapy, compliance

1. Барсурэн Ц., Максикова Т.М., Калягин А.Н., Бабанская Е.Б. Особенности течения и ведения артериальной гипертонии у населения Монгольской народной республики // Сибирский медицинский журнал (Иркутск). - 2015. - Т. 138, № 7. - С. 113-117

2. Комитет экспертов Всероссийского научного общества кардиологов. Кардиоваскулярная профилактика. Национальные рекомендации // Кардиоваскулярная терапия и профилактика. - 2011. - Т. 10, Прил. 2, № 6. - С. 3-64

3. Муромцева Г.А., Концевая А.В., Константинов В.В., Артамонова Г.В., Гатагонова Т.М., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В., Ильин В.А., Конради А.О., Либис Р.А., Минаков Э.В., Недогода С.В., Ощепкова Е.В., Романчук С.В., Ротарь О.П., Трубачева И.А., Деев А.Д., Шальнова С.А., Чазова И.Е., Шляхто Е.В., Бойцов С.А. от лица исследователей ЭССЕ-РФ. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ // Кардиоваскулярная терапия и профилактика. - 2014. - № 13 (6). -С. 4-11. doi: 10.15829/1728-8800-2014-6-4-11

4. Оганов Р.Г., Тимофеева Т.Н., Колтунов И.Е., Константинов В.В., Баланова Ю.А., Капустина А.В., Лельчук И.Н., Шальнова С.А., Деев А.Д. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003-2010 гг. // Кардиоваскулярная терапия и профилактика. - 2011. - № 10 (1). - С. 9-13

5. Протасов К.В., Мягмарсурен Т. Артериальная гипертензия у работников железнодорожного транспорта Монголии: распространенность, клинические особенности, взаимосвязи с факторами кардиоме-таболического риска // Сибирский медицинский журнал (Иркутск). - 2013. - № 6. - С. 122-126

6. Шальнова С.А. Эпидемиология артериальной гипертензии в России: портрет больного // Артериальная гипертензия. - 2008. - № 2 (2). - С. 5-10

7. Abegaz T.M., Shehab A., Gebreyohannes E.A., Bhagavathula A.S., Elnour A.A. (2017). Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore), 96 (4), e5641. doi: 10.1097/MD.0000000000005641.

8. Alsabbagh M.H., Lemstra M., Eurich D., Lix L.M., Wilson T.W., Watson E., Blackburn D.F. (2014). Socioeconomic status and nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Value Health, 17 (2), 288-296. doi: 10.1016/j.jval.2013.11.011.

9. Burnier M. (2017). Drug adherence in hypertension. Pharmacol Res, 125 (Pt B), 142-149. doi: 10.1016/j.phrs.2017.08.015.

10. Chimeddamba O., Ayton D., Bazarragchaa N., Dorjsuren B., Peeters A., Joyce C. (2016). The adoption of roles by primary care providers during implementation of the new chronic disease guidelines in urban Mongolia: a qualitative study. Int J Environ Res Public Health, 13 (4), 407. doi: 10.3390/ijerph13040407.

11. Demaio A.R., Otgontuya D., de Courten M., Bygbjerg I.C., Enkhtuya P., Meyrowitsch D.W., Oyunbileg J. (2013). Hypertension and hypertension-related disease in Mongolia; findings of a national knowledge, attitudes and practices study. BMC Public Health, 13, 194. doi: 10.1186/1471-2458-13-194.

12. Düsing R., Waeber B., Destro M., Santos Maia C., Brunel P. (2017). Triple-combination therapy in the treatment of hypertension: a review of the evidence. J Hum Hypertens, 31 (8), 501-510. doi: 10.1038/jhh.2017.5.

13. Ene-Iordache B., Perico N., Bikbov B., Carminati S., Remuzzi A., Perna A., Islam N., Bravo R.F., Aleckovic-Halilovic M., Zou H., Zhang L., Gouda Z., Tchokhonelidze I., Abraham G., Mahdavi-Mazdeh M., Gallieni M., Codreanu I., Togtokh A., Sharma S.K., Koirala P., Uprety S., Ulasi I., Remuzzi G. (2016). Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health, 4 (5), e307- e319. doi: 10.1016/S2214-109X(16)00071-1.

14. Gupta P., Patel P., Horne R., Buchanan H., Williams B., Tomaszewski M. (2016). How to screen for non-adherence to antihypertensive therapy. Curr Hypertens Rep, 18 (12), 89.

15. Gwadry-Sridhar F.H., Manias E., Lal L., Salas M., Hughes D.A., Ratzki-Leewing A., Grubisic M. (2013). Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health, 16 (5), 863-871. doi: 10.1016/j.jval.2013.03.1631.

16. Jesus N.S., Nogueira A.D., Pachu C.O., Luiz R.R., Oliveira G.M. (2016)/ Blood pressure treatment adherence and control after participation in the ReHOT. Arq Bras Cardiol, 107 (5), 437-445. doi: 10.5935/abc.20160165.

17. Khatib R., Schwalm J.D., Yusuf S., Haynes R.B., McKee M., Khan M., Nieuwlaat R. (2014). Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoS One, 9 (1), e84238. doi: 10.1371/journal.pone.0084238.

18. Komatsu F., Hasegawa K., Watanabe S., Kawabata T., Yanagisawa Y., Kaneko Y., Miyagi S., Sakuma M., Kagawa Y., Ulziiburen C., Narantuya L. (2004). Comparison of electrocardiogram findings and lifestyles between urbanized people and ger-living people in Ulaanbaatar, Mongolia. Atherosclerosis, 175 (1), 101-108. doi: 10.1016/j.athero-sclerosis.2004.03.005.

19. Krousel-Wood M., Hyre A., Muntner P., Morisky D. (2005). Methods to improve medication adherence in patients with hypertension: currentstatus and future directions. Curr Opin Cardiol, 20 (4), 296-300. doi: 10.1097/01.hco.0000166597.52335.23.

20. Li G., Wang H., Wang K., Wang W., Dong F., Qian Y., Gong H., Xu G., Li Y., Pan L., Wang B., Zhu G., Shan G. (2016). Prevalence, awareness, treatment, control and risk factors related to hypertension among urban adults in Inner Mongolia 2014: differences between Mongolian and Han populations. BMC Public Health, 16, 294. doi: 10.1186/s12889-016-2965-5.

21. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Böhm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J., Nilsson P.M., Ruilope L.M., Schmieder R.E., Sirnes P.A., Sleight P., Viigimaa M., Waeber B., Zannad F. (2014)/ 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press, 23 (1), 3-16. doi: 10.3109/08037051.2014.868629.

22. Margolis K.L., Asche S.E., Bergdall A.R., Dehmer S.P., Maciosek M.V., Nyboer R.A., O’Connor P.J., Pawloski P.A., Sperl-Hillen J.M., Trower N.K., Tucker A.D., Green B.B. (2015). A successful multifaceted trial to improve hypertension control in primary care: why did it work? J Gen Intern Med, 30 (11), 1665-1672. doi: 10.1007/s11606-015-3355-x.

23. Mendis S., Puska P., Norrving B. (eds.). (2011). Global atlas on cardiovascular disease prevention and control. Geneva, 155 p.

24. Mendis S. (2014). Global status report on non-communicable diseases. Geneva, 280 p.

25. Moharamzad Y., Saadat H., Nakhjavan Shahraki B., Rai A., Saadat Z., Aerab-Sheibani H., Naghizadeh M.M., Morisky D.E. (2015). Validation of the Persian version of the 8-item Morisky Medication Adherence Scale (MMAS-8) in Iranian hypertensive patients. Glob J Health Sci, 7 (4), 173-183. doi: 10.5539/gjhs.v7n4p173.

26. Narantuya L. (2006). Mongolian STEPS Survey on the prevalence on noncommunicable disease risk factors. Ulaanbaatar, 145 p.

27. Nielsen J.О., Shrestha A.D., Neupane D., Kallestrup P. (2017). Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects. J Hum Hypertens, 31 (1), 14-21. doi: 10.1038/jhh.2016.31.

28. Oliveira-Filho A.D., Morisky D.E., Neves S.J., Costa F.A., de Lyra D.P. (2014). The 8-item Morisky Medication Adherence Scale: validation of a Brazilian-Portuguese version in hypertensive adults. Res Social Adm Pharm, 10 (3), 554561. doi: 10.1016/j.sapharm.2013.10.006.

29. Otgontuya D., Oum S., Palam E., Rani M., Buckley B.S. (2012). Individual-based primary prevention of cardiovascular disease in Cambodia and Mongolia: early identification and management of hypertension and diabetes mellitus. BMC Public Health, 12, 254. doi: 10.1186/14712458-12-254.

30. Oyunbileg J. (2009). Mongolian STEPS Survey on the prevalence on noncommunicable disease risk factors. Ulaanbaatar, 151 p.

31. Peacock E., Krousel-Wood M. (2017). Adherence to antihypertensive therapy. Med Clin North Am, 101 (1), 229-245. doi: 10.1016/j.mcna.2016.08.005.

32. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L., Cooney M.T., Corrà U., Cosyns B., Deaton C., Graham I., Hall M.S., Hobbs F.D., Lөchen M.L., Löllgen H., Marques-Vidal P., Perk J., Prescott E., Redon J., Richter D.J., Sattar N., Smulders Y., Tiberi M., van der Worp H.B., van Dis I., Verschuren W.M.; Authors/Task Force Members. (2016). 2016 European guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J, 37 (29), 2315-2381. doi: 10.1093/eurheartj/ehw106.

33. Rabbia F., Fulcheri C., Di Monaco S., Covella M., Perlo E., Pappaccogli M., Veglio F. (2016). Adherence to antihypertensive therapy and therapeutic dosage f antihypertensive drugs. High Blood Press Cardiovasc Prev, 23 (4), 341-345. doi: 10.1007/s40292-016-0158-z.

34. Schroeder K., Fahey T., Ebrahim S. (2004). Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev, (2), CD004804.

35. Souza AC, Borges JW, Moreira TM. (2016). Quality of life and treatment adherence in hypertensive patients: systematic review with meta-analysis. Rev Saude Publica, 50, 71. doi: 10.1590/S1518-8787.2016050006415.

36. Sun Z., Zheng L., Xu C., Li J., Zhang X., Liu S., Li J., Hu D., Sun Y. (2008). Prevalence of prehypertension, hypertension and, associated risk factors in Mongolian and Han Chinese populations in Northeast China. IntJ Cardiol, 128 (2), 250-254. doi: 10.1016/j.ijcard.2007.08.127.

37. Zhang C.Y., Niu G.M., Zhao S.G., Arong, Wang Z.G., Jiang M.F., Huri L. (2012). Prevalence, detection, management, and control of hypertension in the population of Mongolian and Han nationalities with age > 55 years in a pastoral area of Inner Mongolia Autonomous Region. Zhonghua Xin Xue Guan Bing Za Zhi, 40 (9), 786-790.

38. Zullig L.L., Stechuchak K.M., Goldstein K.M., Olsen M.K., McCant F.M., Danus S., Crowley M.J., Oddone E.Z., Bosworth H.B. (2015). Patient-reported medication adherence barriers among patients with cardiovascular risk factors. J Manag Care Spec Pharm, 21 (6), 479-485. doi: 10.18553/jmcp.2015.21.6.479.